Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric trial of stapokibart in moderate-to-severe atopic dermatitis
CTR20251604Phase 3Active
- Sponsor
- Keymed Biosciences
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of stapokibart in atopic dermatitis (AD), sponsored by Keymed Biosciences. Started May 2025; status: active.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20251604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251604.